AllSci News

Systematic, data-driven science coverage · Saturday, August 8, 2026
The AllSci BriefSystematic R&D and deal news. Daily.
Most Read
Business

Pfizer Q2'26: Mevrometostat, tilrekimig and sigvotatug vedotin shape pipeline outlook

Pfizer Q2'26: Mevrometostat, tilrekimig and sigvotatug vedotin shape pipeline outlook
Business

Gilead Q2'26: BIC/LEN nears approval as weekly HIV pipeline expands

Gilead Q2'26: BIC/LEN nears approval as weekly HIV pipeline expands
Business

CSPC and AstraZeneca establish biologics manufacturing joint venture in China

CSPC and AstraZeneca establish biologics manufacturing joint venture in China
Business

Novo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances

Novo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances
Business

Mironid raises USD 46m to advance first-in-class ADPKD therapy

Mironid raises USD 46m to advance first-in-class ADPKD therapy
Editor’s Picks
Replimune secures accelerated approval for oncolytic viral therapy TudriqevRegulatory & Policy

Replimune secures accelerated approval for oncolytic viral therapy Tudriqev

· 2 min read
China accepts NDA for Alebund's phosphate binder AP301 after Phase III successRegulatory & Policy

China accepts NDA for Alebund's phosphate binder AP301 after Phase III success

· 1 min read
Washington University wins NIA grant to study immune clearance in Alzheimer's diseaseDiscovery

Washington University wins NIA grant to study immune clearance in Alzheimer's disease

· 3 min read
Latest NewsView all news →
BioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer data
Regulatory & Policy

BioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer data

Sweden-based BioInvent International AB (Nasdaq Stockholm: BINV) announced receipt of US FDA Fast Track Designation for BI-1808, a first-in-class anti-tumor...

8h agoNeurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study
Development

Neurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study

Neurocrine Biosciences (Nasdaq: NBIX) has dosed the first participants in a Phase I first-in-human study of NBIP-1968, an internally discovered...

8h agoSino Bio's benmelstobart-anlotinib regimen adds new China indication in first-line squamous NSCLC
Regulatory & Policy

Sino Bio's benmelstobart-anlotinib regimen adds new China indication in first-line squamous NSCLC

China's National Medical Products Administration (NMPA) has approved a new first-line regimen for locally advanced or metastatic squamous non-small cell...

8h agoArcturus and CSL Seqirus terminate sa-mRNA vaccine partnership
Business

Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership

San Diego-based Arcturus Therapeutics (Nasdaq: ARCT) has terminated its self-amplifying mRNA collaboration with CSL Seqirus through a settlement agreement,...

8h agoBioMarin drops BMN 401 following unsuccessful pivotal trial
Business

BioMarin drops BMN 401 following unsuccessful pivotal trial

BioMarin Discontinues BMN 401 Across All Indications After Pivotal ENPP1 Trial Fails Co-Primary Endpoints

8h agoShape and Rett Syndrome Research Trust advance AI-designed RNA editor for R168X mutation
Business

Shape and Rett Syndrome Research Trust advance AI-designed RNA editor for R168X mutation

Seattle-based Shape Therapeutics and the Rett Syndrome Research Trust (RSRT) announced a partnership to advance SHP-401, an investigational RNA editing gene...

9h agoTarsus secures USD 125m to fund Alkeus acquisition and expand eye care pipeline
Business

Tarsus secures USD 125m to fund Alkeus acquisition and expand eye care pipeline

Irvine, California-based Tarsus Pharmaceuticals (Nasdaq: TARS) announced an oversubscribed USD 125 million private investment in public equity (PIPE)...

9h agoDispatch advances synthetic-antigen CAR T platform into first-in-human testing
Development

Dispatch advances synthetic-antigen CAR T platform into first-in-human testing

Dispatch Bio has dosed the first patient in a Phase I study of DISP-10 immunotherapy, a combination approach pairing a tumor-specific virus with an approved...

10h ago
The AllSci BriefSystematic R&D and deal news. Daily.
Vistagen reports exploratory Phase II miss for social anxiety drug candidate
Development

Vistagen reports exploratory Phase II miss for social anxiety drug candidate

South San Francisco-based Vistagen Therapeutics (Nasdaq: VTGN) reported topline results on August 6 from an exploratory Phase II study of fasedienol nasal...

10h agoEdding Genor tries trispecific PD-1/CTLA-4/VEGF antibody against breast cancer
Development

Edding Genor tries trispecific PD-1/CTLA-4/VEGF antibody against breast cancer

Hong Kong-listed Edding Genor Group Holdings Limited (HKEX: 06998) announced on August 6 that the first subject has been dosed in the Phase Ib/II clinical...

10h agoReCode expands cystic fibrosis gene editing push with new CF Foundation backing and unnamed partner
Business

ReCode expands cystic fibrosis gene editing push with new CF Foundation backing and unnamed partner

Mountain View, California-based ReCode Therapeutics announced a research collaboration with an undisclosed gene editing company to develop a CFTR-correcting...

10h agoBiogen closes deal for USD 1b buyout of RayThera
Business

Biogen closes deal for USD 1b buyout of RayThera

Biogen (Nasdaq: BIIB) has completed its acquisition of RayThera Inc., a San Diego-based small-molecule immunology company, for a total potential...

10h agoEU clears label expansion for Bavarian Nordic's Mpox vaccine to children as young as two
Regulatory & Policy

EU clears label expansion for Bavarian Nordic's Mpox vaccine to children as young as two

The European Commission has approved a label extension for Imvanex (MVA-BN), Denmark-based Bavarian Nordic's (OMX: BAVA) non-replicating smallpox and mpox...

11h agoTranscenta sells CDMO assets to WuXi Bio to focus on drug pipeline
Business

Transcenta sells CDMO assets to WuXi Bio to focus on drug pipeline

Transcenta Holding Limited (HKEX: 6628) has agreed to sell its Hangzhou contract development and manufacturing organization assets to WuXi Biologics...

11h agoUniversity of Colorado renews work on CAR-phagocyte pediatric brain cancer therapy
Discovery

University of Colorado renews work on CAR-phagocyte pediatric brain cancer therapy

The University of Colorado Cancer Center has received a USD 1.28 million NIH R01 renewal from the National Cancer Institute to develop chimeric antigen...

11h ago